Posterior Circulation Stroke
This course provides a review of the clinical characteristics of posterior circulation stroke symptoms and an evidence-based review of the implication of clinical trial data on treatment options.
Adult and Pediatric Neurologists, Neurosurgeons, Stroke Neurologists, Neuroradiologists, Diagnostic Radiologists, Critical Care Physicians, Neurointensivists, Emergency Medicine Physicians, Internal Medicine Physicians, Interventional Neuroradiologists, Family Physicians, General Internists, Rehabilitation and Pain Management Specialists, Clinical Pharmacists, as well as other specialists interested in the field of neuroscience.
- Identify patients with posterior circulation stroke.
- Recognize the limitations associated with clinical scale assessments that determine eligibility for acute reperfusion treatment.
- Determine when to triage posterior circulation stroke patients to ICU, neuro-stepdown or floor.
- Select patients for early surgical decompression or medical cytotoxic edema treatment.
Brett Kissela, M.D., M.S.
Professor and Chair
Department of Neurology and Rehabilitation Medicine
Senior Associate Dean of Clinical Research
University of Cincinnati College of Medicine
Chief of Research Services, UC Health
Brett Kissela, M.D., indicated that he is a consultant with Allegan and Ipsen and on the adjudication clinical trail committee for AbbVie and Janssen.
Kevin Abrams, M.D., indicated that he is a consultant and shareholder with Keystone Heart.
Guilherme Dabus, M.D., indicated that he is a consultant for Microvention/Terumo, Medtronic, Penumbra and Cerenovus, and on the speakers bureau for Microvention/Terumo, Medtronic and Penumbra. He is a proctor for Medtronic. Dr. Dabus is also a shareholder with Surpass Medical/Stryker, Medina/Medtronic, InNeuro Co and Three Rivers Medical.
Daniel D’Amour, M.D., Felipe De Los Rios, M.D., Karel Fuentes, M.D., Sergio Gonzalez-Arias, M.D., Ph.D., Kunal Patel, M.S., Amy K. Starosciak, Ph.D., and Jayme Strauss, R.N., MSN, indicated that neither they nor their spouse/partner have relevant financial relationships with commercial interest companies, and they will not include off-label or unapproved product usage in their presentations or discussions.
Bruno V. Gallo, M.D., indicated that he is on speakers bureau for Teva Pharmaceuticals and Sunovion Pharmaceuticals. He receives grant support for Medtronic International, Pfizer Pharmaceuticals, Glaxo-SmithKline and St. Jude Medical, Inc. Dr. Gallo serves as a consultant for Cyberonics, Teva Pharmaceuticals, St. Jude Medical, ONS Inc. and Sugimon LLC.
Italo Linfante, M.D., indicated that he is a consultant for Medtronic, Stryker and Penumbra. He is a stockholder with InNeuro Co.
Alberto Pinzon-Ardila, M.D., indicated that he is on the speakers bureau for Sunovion Pharmaceuticals and UCB.
Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 0.50 AMA PRA Category 1 Credit™
- 0.50 General certificate of attendance
- 0.50 Florida Board of Pharmacy
This site is supported on the most recent stable releases of the following browsers:
This site is supported on the following mobile devices:
If you are experiencing technical difficulties or have received an error message, please send an email to CME@baptisthealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.